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Glioblastoma multiforme (GBM) is the most common and lethal type of primary brain tumor. Although nonmetastasizing, GBM cells can diffusely infiltrate the normal cerebral 
cortex, resulting in death, with a median survival of 14 months despite combined surgical resection, radiotherapy, and chemotherapy. Standard therapy has been relatively 
ineffective for many reasons, not the least of which is the extensive invasion of GBM cells into normal brain tissue, which limits the extent of surgical resection and high dose 
radiotherapy for fear of unacceptable permanent neurological damage to the patient. Traditional chemotherapy has limited value because of poor blood-brain barrier penetration, 
intrinsic glioma resistance, and nonselective toxicity. Thus, the development of improved therapies rests on a greater understanding of the biology of GBM.
Several molecular and genomic datasets have recently been generated that have allowed us to identify at least four subtypes of GBM: classical, mesenchymal, proneural, and 
neural. Classical subtype is characterized by chromosome 7 amplification, focal CDKN2A deletion, chromosome 10 loss, EGFR amplification/mutation, a lack of TP53 muta-
tions, RB pathway alterations, NES expression, and high Notch and Hedgehog pathway activity. Mesenchymal subtype has frequent mutation or loss of NF1, TP53, and PTEN; 
frequent chromosomal aberrations at CDK6, MET, PTEN, CDKN2A, and RB1 loci; activation of NF-κB and TNF pathways; and overexpression of MET, CD44, MERTK, and CHI3L. 
Proneural subtype frequently has IDH1 or IDH2 mutations; PDGFR amplification or PIK3CA/PIK3R1 mutations; loss or mutation of TP53, CDKN2A, and PTEN; activation of HIF, 
PI3K, and PDGFR pathways; OLIG2, NKX2-2, and PDGFRA oligodendrocytic marker expression; and TCF4, SOX, DCX, DLL3, and ASCL1 proneural marker expression. G-CIMP 
methylator phenotype characterizes a subgroup of proneural GBM that may represent a distinct tumor type. Neural subtype is related to the classical subtype but has a higher 
frequency of TP53 mutation; EGFR amplification/overexpression; and NEFL, GABRA1, SYT1, and SLC12A5 neuronal marker expression.
The traditional strategy in oncology of attempting tumor eradication has been challenged with the concept that even without killing every last cancer cell, interfering with 
critical aspects of tumor biology may translate to significant clinical benefit. The accompanying SnapShot diagrammatically captures several key biological properties and the 
responsible molecular pathways that represent the current focus of GBM clinical trials.
Proliferation
Cell cycle deregulation in GBMs is in part a result of abnormal signaling by several different receptor tyrosine kinases (RTKs) including EGFR, PDGFR, and MET. These RTKs 
act downstream to deregulate MAPK and PI3K pathways. The greatest emphasis in targeted drug development for GBM has focused on RTK inhibitors. Recent preclinical and 
clinical work indicates redundancy in RTK signaling, suggesting the need for simultaneous inhibition of multiple RTKs or inhibition of downstream signals; hence, there has been 
great interest in the clinical testing of inhibitors of PI3K, AKT and the TORC1/2 complexes. Although there was an initial interest in CDK inhibitors, early clinical data suggest 
nonselectivity of the agents and toxicity to normal proliferating cells.
Metabolism
GBMs, like other tumors, prefer aerobic glycolysis (a phenomenon known as the Warburg effect). Preclinical data has demonstrated a dependency on altered glucose and fatty 
acid metabolism, but drugs that selectively interfere with these biochemical pathways are only now coming into clinical development. This altered metabolism also results in the 
generation of excess reactive oxygen species (ROS), which has led to the development of several new agents that interfere with the GBM cell’s ability to neutralize ROS. More-
over, about 80% of low grade gliomas and about 5%–10% of GBMs have mutations in IDH1 or IDH2 causing altered 2-hydroxyglutarate production and altered DNA methylation, 
which has led to trials with IDH1 inhibitors and demethylating agents to address the epigenomic changes associates with this genotype.
Glioma Stem Cells
There is increasing evidence that only a subpopulation of cells within a GBM truly has tumorigenic properties. The nature of these cells remains controversial, but it is clear that 
at least some canonical stem cell signaling pathways are operative in glioma stem/initiating cells (GSCs). It appears that Notch signaling is vital for proliferation and survival of 
GSCs, leading to a series of clinical trials in GBM with γ-secretase inhibitors. There is also evidence to suggest that at least some GSC lines are dependent on the Hedgehog and 
Wnt pathways, paving the way for clinical trials with Smo inhibitors and inhibitors of Wnt ligands.
Angiogenesis
GBMs are highly angiogenic and vasculogenic. VEGF is a primary mediator of tumor angiogenesis and GBM-associated cerebral edema. Anti-VEGF bevacizumab can signifi-
cantly decrease cerebral edema and potently inhibit tumor growth in patients. Small molecule inhibitors of VEGFR, however, have proven less effective in the clinic to date. 
Ongoing clinical trials are investigating agents that target other angiogenic factors and their receptors (e.g., PDGFR, c-KIT, FGFR) as well as endothelial cell-associated integrins.
Invasion
Since GBMs generally kill via their invasiveness, patient morbidity and survival might be greatly improved by inhibiting invasion. PI3K and MAPK pathway deregulation has been 
linked with increased cellular motility via EGFR signaling in GBM. Amplification and/or overexpression of the HGF/MET pathway have also been implicated in GBM invasion, lead-
ing to clinical trials of MET inhibitors. Recently, TRKA has been implicated as an important mediator of GBM stem cell migration, leading to the testing of novel TRK inhibitors.
It is unlikely that inhibiting any one pathway will result in dramatic clinical benefit, but it is hoped that interfering with two or more key biological functions will. For example, recent 
preclinical and clinical data suggest that VEGF inhibition leads to increased GBM invasiveness. New clinical trials, therefore, are now being developed to combine angiogenic 
inhibitors such as bevacizumab with MET and/or TRK inhibitors. These future trials likely hold the most promise for improved therapy for this devastating disease.
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